共 50 条
Four-Repeat Tauopathies: Current Management and Future Treatments
被引:31
作者:
VandeVrede, Lawren
[1
]
Ljubenkov, Peter A.
[1
]
Rojas, Julio C.
[1
]
Welch, Ariane E.
[1
]
Boxer, Adam L.
[1
]
机构:
[1] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA
关键词:
4R-tauopathy (4R-tau);
progressive supranuclear palsy (PSP);
Richardson's syndrome (PSP-RS);
corticobasal syndrome (CBS);
corticobasal degeneration (CBD);
atypical parkinsonism;
PROGRESSIVE SUPRANUCLEAR PALSY;
FRONTOTEMPORAL LOBAR DEGENERATION;
PLACEBO-CONTROLLED TRIAL;
ANTI-TAU ANTIBODY;
QUALITY-OF-LIFE;
CORTICOBASAL DEGENERATION;
ALZHEIMERS-DISEASE;
DOUBLE-BLIND;
PARKINSONS-DISEASE;
DIAGNOSTIC-CRITERIA;
D O I:
10.1007/s13311-020-00888-5
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Four-repeat tauopathies are a neurodegenerative disease characterized by brain parenchymal accumulation of a specific isoform of the protein tau, which gives rise to a wide breadth of clinical syndromes encompassing diverse symptomatology, with the most common syndromes being progressive supranuclear palsy-Richardson's and corticobasal syndrome. Despite the lack of effective disease-modifying therapies, targeted treatment of symptoms can improve quality of life for patients with 4-repeat tauopathies. However, managing these symptoms can be a daunting task, even for those familiar with the diseases, as they span motor, sensory, cognitive, affective, autonomic, and behavioral domains. This review describes current approaches to symptomatic management of common clinical symptoms in 4-repeat tauopathies with a focus on practical patient management, including pharmacologic and nonpharmacologic strategies, and concludes with a discussion of the history and future of disease-modifying therapeutics and clinical trials in this population.
引用
收藏
页码:1563 / 1581
页数:19
相关论文